Associations - FGFR2 amplification

FGFR2 amplification FGFR2 amplification	Gastric Cancer Gastric Cancer	TAS 120 Sensitive: C2 – Inclusion Criteria
FGFR2 amplification FGFR2 amplification	Breast Cancer Breast Cancer	TAS 120 Sensitive: C2 – Inclusion Criteria
FGFR2 amplification FGFR2 amplification	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria
FGFR2 amplification FGFR2 amplification	Breast Cancer Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria
FGFR2 amplification FGFR2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	ABSK-091 Sensitive: C3 – Early Trials
FGFR2 amplification FGFR2 amplification	Gastric Cancer Gastric Cancer	Debio 1347 Resistant: C3 – Early Trials
FGFR2 amplification FGFR2 amplification	Breast Cancer Breast Cancer	TKI258 Sensitive: C3 – Early Trials
FGFR2 amplification FGFR2 amplification	Breast Cancer Breast Cancer	Debio 1347 Sensitive: C3 – Early Trials
FGFR2 amplification FGFR2 amplification	Breast Cancer Breast Cancer	ponatinib Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	TAS 120 Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Colorectal Cancer CRC	eFT226 Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Gastric Cancer Gastric Cancer	erdafitinib Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Colorectal Cancer CRC	ponatinib Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Non Small Cell Lung Cancer NSCLC	eFT226 Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Gastric Cancer Gastric Cancer	ponatinib Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Breast Cancer Breast Cancer	eFT226 Sensitive: D – Preclinical
FGFR2 amplification FGFR2 amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	nintedanib Sensitive: D – Preclinical